The use of antiemetic drugs for patients receiving chemotherapy with low or minimal emetic risk has been recognized as a growing concern for health care costs and patients' welfare. Relatively few studies have examined antiemetic prophylaxis or treatment of emesis associated with chemotherapy with lower emetic risk.
nese Society of Clinical Oncology 8 recommend single-agent therapy with dexamethasone for patients receiving chemotherapy with low emetic risk for the acute-phase CINV, whereas the Multinational Association of Supportive Care in Cancer/ European Society for Medical Oncology 10 recommend singleagent therapy with dexamethasone, a serotonin receptor antagonist, or a dopamine receptor antagonist. These organizations have slight differences in their recommended prophylactic antiemetic drugs for patients at low emetic risk. 11 All 3 guidelines recommend no prophylactic drugs for patients receiving chemotherapy with minimal emetic risk. Moreover, the antiemetic guidelines explain that CINV in the delayed phase is not a major problem for patients undergoing chemotherapy with low or minimal emetic risk. 8 Adherence to the antiemetic guidelines has been repeatedly reported to be suboptimal in community practices. [12] [13] [14] [15] [16] [17] [18] Few studies have reported the patterns of prescribing antiemetic drugs for lower emetic risk groups. In a single-facility study, 14 adherence to guidelines in the low emetic potential group was only 11% because the remaining patients received a serotonin receptor antagonist in addition to corticosteroids. However, serotonin receptor antagonists, including the second-generation granisetron hydrochloride, have been proven to provide little benefit as primary prophylaxis in patients receiving chemotherapy with a low emetic risk. 19 Unfortunately, few clinical trials of antiemetic prophylaxis or treatment of emesis associated with these drugs with low emetic risks have been published. 20 This lack may lead to overtreatment with antiemetic drugs for patients at lower risk. The overuse of health care services has recently gained increasing public attention owing to rising health care expenditures worldwide. [21] [22] [23] Responding to the Choosing Wisely campaign by the American Board of Internal Medicine Foundation, the American Society of Clinical Oncology listed the use of antiemetic drugs targeting chemotherapy with high emetic risk for chemotherapy with low or minimal emetic risk as one of "the things that patients and doctors should question." 24(p1) Despite the growing concern, to our knowledge, only the single small-scale study 14 mentioned above has examined the overuse of prophylactic antiemetic drugs in a hospital setting. More important, no study, to our knowledge, has performed a largescale investigation into the pattern of prescribing prophylactic antiemetics for lower emetic risk groups. The present study aimed to investigate the pattern of prescribing prophylactic antiemetic drugs using a Japanese nationwide database that contains data submitted from the designated cancer hospitals.
Methods

Data Source
This study is a secondary analysis of health insurance claims data linked with the hospital-based cancer registry, 25 which were collected for research on evaluating the quality of health care for patients with cancer. 26 Most of the participating hospitals were among 397 Cancer Care Hospitals designated by the Ministry of Health, Labor, and Welfare, Tokyo, Japan. We analyzed these data for patients diagnosed in 2011 with breast, lung, colorectal, stomach, cervical, and prostate cancer. We extracted the insurance claim data from September 1, 2010, through December 31, 2012, from 122 voluntarily participating hospitals that provided data. The complete hospitalbased cancer registry is estimated to contain reports on 66.9% of the new cancer cases in 2011 for all of Japan. 25 The hospitals that we sampled for this study are estimated to have provided care to 18.9% of the new patients with cancer in 2011. We analyzed data on patients with any of the 7 cancers in the database, 20 years or older, who received intravenous chemotherapy with minimal or low emetic risk. We excluded data on patients who had advanced clinical stages of cancer, specifically TNM stage IV clinical classification of malignant tumors. The institutional review board at the National Cancer Center in Japan approved this study. Owing to the retrospective nature of the database analysis, the need for informed consent was waived.
Identification of Chemotherapy Claims
We identified claims for intravenous chemotherapy with minimal or low emetic risks based on the Japanese Society of 
Statistical Analysis
Data were analyzed from March 20, 2014, to June 30, 2016. We examined the pattern of prescribing prophylactic antiemetic drugs, including neurokinin 1 (NK 1 ) receptor antagonists, serotonin receptor antagonists, and dexamethasone, for patients who received intravenous chemotherapy with minimal or low emetic risk. The percentage of patients receiving chemotherapy who were given prophylactic antiemetic drugs was calculated. The unit of analysis was chemotherapy administration, which was defined as the day on which the patient received chemotherapy. The patients' emetic risk was classified based on the highest risk category among the chemotherapeutic agents prescribed on the same day. A patient was counted 2 or more times if he or she received chemotherapy multiple times. The SEs were adjusted for the clustering of chemotherapy administration within patients using HuberWhite estimators. 27 Antiemetic drugs that were prescribed on the same day as chemotherapeutic agents were regarded as prophylactic. We calculated the percentage of patients with chemotherapy administration who were prescribed antiemetic drugs according to cancer sites and clinical stages and conducted a 2-sided χ 2 test.
We also performed an additional analysis to confirm the robustness of the results by limiting the sample population to men 65 years or older. These patients were considered to be at low risk for CINV. 28 We performed these analyses to test whether physicians based their decision of whether to use prophylactic antiemetic drugs on the individual patient's condition. If they did, the percentage of patients who were prescribed prophylactic antiemetic drugs in this group would be less than in the younger population, by the limitation of the sample. To estimate potential savings, the cost of unnecessary antiemetic drugs, according to recommendations from the Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology, was examined using the Japanese National Health Insurance drug price list from 2011 (http://www.okusuri110.com/yaka /yaka_search.html). All analyses were performed using STATA software (version 13.1; StataCorp).
Results
We extracted 73 577 occurrences of chemotherapy administration that had low (n = 50 958) or minimal ( Table 2 show the percentages of chemotherapy administration where the patient was prescribed prophylactic antiemetic drugs for chemotherapy with minimal or low emetic risk. Although no prophylactic antiemetic drugs were recommended by any of the clinical practice guidelines, 12.4% of the chemotherapy with minimal emetic risk was accompanied by an antiemetic drug. Specifically, 6.3% (95% CI, 5.4%-7.4%) of the chemotherapy with minimal emetic risk involved prescription of dexamethasone; 2.9% (95% CI, 2.2%-3.7%), prescription of a serotonin receptor antagonist; and 2.8% (95% CI, 2.2%-3.4%), prescription of a serotonin receptor antagonist and dexamethasone. Among patients in the low emetic risk group, 47.8% (95% CI, 46.5%-49.2%) of the chemotherapy included prescription of a serotonin receptor antagonist and dexamethasone. Occasionally (2.8%; 95% CI, 2.5%-3.1%), chemotherapy with minimal emetic risk included prescription of a combination of an NK 1 receptor antagonist, a serotonin receptor antagonist, and dexamethasone.
In the minimal emetic risk group, 87.9% of the chemotherapy was administered at an outpatient clinic. In the outpatient group, 5.2% (95% CI, 4.2%-6.3%) of the chemotherapy with minimal emetic risk included prescription of dexamethasone, whereas 10.8% (95% CI, 8.8%-13.2%) of the chemotherapy with minimal emetic risk administered to inpatients in this group included prescription of an serotonin receptor antagonist and dexamethasone, and 16.8% (95% CI, 12.8%-21.6%) included prescription of a serotonin receptor antagonist.
In the low emetic risk group, 27.3% of the chemotherapy was administered to inpatients. In the inpatient group, 33.7% (95% CI, 31.7%-35.9%) of the chemotherapy included the prescription of a serotonin receptor antagonist and dexamethasone. In the outpatient group, 53.1% (95% CI, 51.6%-54.7%) of the chemotherapy included the prescription of a serotonin receptor antagonist and dexamethasone.
In both emetic risk groups, the frequency of chemotherapy that involved the prescription of potentially unnecessary antiemetic drugs differed significantly among clinical stages and cancer sites ( Table 3) . Frequencies for clinical stage ranged from 3.0% (95% CI, 1.2%-7.4%) for stage 0 cancer to 26.1% (95% CI, 22.7%-29.7%) for stage III cancer in the minimal emetic risk group and from 36.5% (95% CI, 27.0%-47.1%) for stage 0 cancer to 52.9% (95% CI, 50.7%-55.2%) for stage III cancer in the low emetic risk group (P < .001). Frequencies ranged from 2.3% (95% CI, 1.7%-3.2%) for breast cancer to 53.0% (95% CI, 47.9%-58.0%) for lung cancer in the minimal emetic risk group and from 27.3% (95% CI, 20.3%-35.7%) for prostate cancer to 60.6% (95% CI, 58.8%-62.3%) for breast cancer in the low emetic risk group (P < .001).
We identified 15 074 occurrences of chemotherapy administration for men who were 65 years or older among the patients in this study. Of these, 13.9% (95% CI, 10.1%-18.9%) in the minimal emetic risk group included prescription of the 2-drug combination of a serotonin receptor antagonist and dexamethasone, and 8.9% (95% CI, 6.2%-12.6%) included prescription of a serotonin receptor antagonist. In the low emetic risk group, 38.9% (95% CI 36.0%-42.0%) included prescription of the 2-drug combination of a serotonin receptor antagonist and dexamethasone. Moreover, hospitalization for chemotherapy occurred in 38% of administrations in the minimal emetic risk group and 48.6% in the low emetic risk group. Inpatients in minimal emetic risk groups were less frequently prescribed a serotonin receptor antagonist and dexamethasone (17.6%; 95% CI, 12.9%-23.6%) compared with inpatients in low emetic risk groups (32.6%; 95% CI, 29.1%-36.3%). The detailed results of this analysis are described in eTables 2 and 3 in the Supplement.
The cost of the prophylactic antiemetic drugs was approximately ¥170 million (US $1.6 million). This cost included ¥7 million (US $70 000) and ¥ 160 million (US $1.5 million) for the chemotherapy administration with minimal and low emetic risk, respectively. Copyright 2017 American Medical Association. All rights reserved.
Copyright 2017 American Medical Association. All rights reserved.
Discussion
We found that a substantial number of patients in Japan receiving chemotherapy with minimal or low emetic risk were prescribed prophylactic antiemetic drugs, even when antiemetic guidelines do not recommend their use. More than 10% of the chemotherapy with minimal emetic risk involved the prescription of at least 1 antiemetic, and about half of the chemotherapy in the low emetic risk group included a combination of 2 antiemetic drugs. Given that chemotherapy with minimal and low emetic risk is reported to cause emesis approximately 10% and 30% of the time, respectively, a 10% prescription rate for the minimal emetic risk group may be reasonable if these patients are accurately identified, but the antiemetic use for the low emetic risk group in this study was far higher than expected. Furthermore, outpatients were more frequently prescribed a 2-drug combination of antiemetics in the low emetic risk group than were inpatients. Because we expect outpatients to be in a much better condition than inpatients, those patients are likely being prescribed antiemetic drugs regardless of their condition. In the minimal emetic risk group, patients with a more advanced stage of cancer tended to be prescribed antiemetic drugs more often, whereas patients in the low emetic risk group had similar rates of antiemetic drug prescription among those with clinical stages I to III cancer. Patients with colorectal or lung cancer in the minimal emetic risk group received antiemetic drugs more often than patients with other cancers. This finding can be explained by the fact that patients with colorectal or lung cancer in the minimal emetic risk group (stage III, 49.0% of chemotherapy administration for patients with colorectal cancer and 63.7% of chemotherapy administration for patients with lung cancer) treated more advanced stage cancer compared with other types of cancer in this group (16.6%-28.2%). Cancer prognosis itself leads to nausea and vomiting, so clinicians may prescribe antiemetic drugs more often for those patients. Our study revealed an opportunity to improve clinical practice by reducing unnecessary care and allocating resources to effective treatment, in particular for the low emetic risk group. One possible reason for the overuse of prophylactic antiemetic drugs is that physicians and patients are too concerned about the adverse effects of chemotherapy that could result in the cessation of the patients' chemotherapy. This possibility is supported by a report that found that poorly controlled CINV led to a delay or refusal of possibly life-saving chemotherapy in 25% to 50% of patients. 29, 30 Nevertheless, the frequency of CINV in patients receiving chemotherapy with low or minimal emetic risk is less than 30%, meaning that most of the prophylactic treatment, if provided, may not be necessary. Furthermore, antiemetic drugs carry a risk for adverse effects, including mild headache, transient elevation of hepatic aminotransferase levels, and constipation, 31,32 which can also interfere with chemotherapy.
Furthermore, prescribing unnecessary medication imposes a financial burden on patients. Physicians and other health care professionals should discuss the benefit and harm of these antiemetic drugs with patients before prescribing the drugs. Another factor that may contribute to overuse of antiemetic drugs is the packaging of these drugs with chemotherapy regimens. Despite more chemotherapeutic agents with low and minimal emetic risk becoming available, 20 to our knowledge, the necessity of antiemetic prophylaxis has never been tested. Because these agents induce little emesis to begin with, but given the lack of clinical evidence, anxiety about CINV experienced in previous chemotherapy regimens with moderate emetic risk may have been applied to the newer drugs despite their having lower emetogenicity. This anxiety could lead to the inclusion of prophylactic antiemetic drugs in future chemotherapeutic regimens and potentially contribute to the overuse of antiemetic drugs. 20 We also found similar levels of use in a demographic of patients who are generally better at controlling their vomiting 33 relative to the overall patient population, which indicates that the use of antiemetic drugs for chemotherapy with low and minimal emetic risk is predetermined, regardless of the individual patient's risk. Recent studies have suggested the importance of identifying a patient's individual risk for CINV. 34, 35 Hospitals should reevaluate their registered chemotherapy regimen to enhance appropriate use of antiemetic drugs. Inpatients in the minimal emetic risk group were frequently prescribed prophylactic antiemetic drugs. In our study, men 65 years or older were more often hospitalized for their chemotherapy and prescribed antiemetic drugs than the rest of the study patients. Elderly patients are at a higher risk for complications related to CINV, such as dehydration, hypotension, and renal impairment. 36 If elderly patients experience CINV during their chemotherapy, such adverse effects could worsen. This finding may explain why more elderly patients were hospitalized and then prescribed prophylactic antiemetic drugs compared with other patients.
Limitations
Our study has several limitations. First, prophylactic antiemetic drugs were defined as those prescribed on the same day as chemotherapy. The antiemetic drugs may actually not be prophylactic but rather therapeutic, resulting in the overestimation of the overuse. Second, oral antiemetic drugs prescribed before the first day of chemotherapy were not taken into account. This process might have caused underestimation of the actual rates of use. Third, physicians' clinical judgment and patients' preferences were not taken into consideration. Such data, including previous experiences of CINV and patients' comorbidities, were not available from the health insurance claims database or the hospital-based cancer registry. Hesketh et al 37 suggested that among patients with cancer who had a history of CINV and received chemotherapy with a low emetic risk, palonosetron hydrochloride was effective in preventing CINV in the acute and delayed postchemotherapy phases. Reasons for and consequences of the use of prophylactic antiemetic drugs should be examined in future studies. Finally, the exact drug dosages and the body surface area of patients were not available from the claims data. Consequently, the emetic risks of patients undergoing chemotherapy using methotrexate and cytarabine may be misclassified. However, in our sample, few patients used these drugs for chemotherapy, and the influence of this misclassification does not seem to be a major concern.
Conclusions
This study illustrates the potential for overuse of prophylactic antiemetics for chemotherapy with minimal and low emetic risks. Prescribing unnecessary antiemetic drugs not only 
